Drug intelligence / Profile preview

rabies antiserum

Development stage
Unknown
Lead developer
Premium Serums and Vaccines
Modality
Antibody-Based Therapeutics
Administration
Intramuscular, Subcutaneous
01

Overview

Rabies antiserum, also known as equine rabies immunoglobulin (ERIG), is a sterile preparation of purified and concentrated immunoglobulin fragments (predominantly F(ab')2) obtained from the plasma of healthy horses immunized against the rabies virus. It is indicated for post-exposure prophylaxis (PEP) of rabies in individuals who have sustained Category III exposures (such as deep bites or scratches) from potentially rabid animals. Rabies antiserum provides immediate passive immunity by locally neutralizing the rabies virus at the site of exposure before it can invade the central nervous system. It is administered via local infiltration in and around the wound, with any remaining volume given intramuscularly, and must be used in conjunction with a full course of active rabies vaccination.

Brand names
AbhayRIGCarigEquirabFavirabPremi-RABPremi-RIGPremi-RIG (FD)Rabix-IGVinrab
Other names
anti-rabies serumequine anti-rabies serumequine rabies immunoglobulinequine rabies immunoglobulin fragmentsERIGrabies immune globulin (equine)rabies immunoglobulin (equine)rabies immunoglobulin, equine
02

Targets

NeuraminidaseRABV-G (Rabies virus glycoprotein)

Beyond the preview

Go deeper on rabies antiserum.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on rabies antiserum.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call